Elanco Animal Health (ELAN) Long-Term Investments (2017 - 2018)
Elanco Animal Health (ELAN) reported Long-Term Investments of $15.3 million for Q4 2018, up 24.39% on a YoY basis from $12.3 million in Q4 2017, and up 2.68% sequentially from $14.9 million in Q3 2018.
Elanco Animal Health (ELAN) Long-Term Investments (2017 - 2018) Analysis & Trends
Elanco Animal Health (ELAN) has 2 years of Long-Term Investments data on file, last reported at $15.3 million in Q4 2018.
- For the quarter ending Q4 2018, Long-Term Investments rose 24.39% year-over-year to $15.3 million; the trailing twelve-month figure through Dec 2018 stood at $15.3 million (up 24.39% YoY), and the FY2018 full-year result was $15.3 million, up 24.39% from the prior year.
- Long-Term Investments advanced to $15.3 million in Q4 2018, from $14.9 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $15.3 million in Q4 2018 to a low of $12.3 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 1.32 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 12.05 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 15.30 Mn |
| Sep 30, 2018 | 14.90 Mn |
| Dec 31, 2017 | 12.30 Mn |